Ochre Bio
PrivateLast Round
Series A
Oct 10, 2022
Total Funding Raised
$39.75M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Ochre Bio operates in Healthcare & Life Sciences and is based in Oxford. Its latest recorded funding round was a Series A round in October 2022.
Ochre Bio is a biotechnology company that develops RNA-based therapies for chronic liver diseases using a discovery platform that integrates machine learning, genomic phenotyping, and perfused human donor livers.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Healthcare Analytics
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Ochre Bio Comparables
Compare Ochre Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Engitix Therapeutics | 84% | |
| Revalia Bio | 83% | |
| HAYA Therapeutics | 82% |
For institutional investors. Book with your work email.
Ochre Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Oct 10, 2022 | ||||
| Seed | Jun 16, 2021 | ||||
| Pre Seed | Mar 18, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Ochre Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Backed VC | Series A, Seed |
| LifeLink Ventures | Series A |
| Khosla Ventures | Series A, Seed |
| Gaingels | Series A |
| Hoxton Ventures | Seed |
| Hermes-Epitek | Series A, Seed |
| Lifeforce Capital | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 24, 2026
Monthly visitors grew 34% MoM, reaching 4.4K.
- Jun 30, 2025
Quin Wills appointed as the new Chief Executive Officer.
For institutional investors. Book with your work email.
Ochre Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Ochre Bio's valuation, stock price, and market status.
Is Ochre Bio a public or private company?
Ochre Bio is a private company.
What is the current stock price of Ochre Bio?
Ochre Bio is a private company, so its shares have no public market price. Caplight tracks Ochre Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Ochre Bio worth (valuation)?
Valuation information for Ochre Bio is not publicly available.
Can I buy Ochre Bio stock?
Ochre Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Ochre Bio's last funding round?
Ochre Bio's most recent funding round was Series A on October 10, 2022.
Who are the main investors in Ochre Bio?
Key investors in Ochre Bio include Khosla Ventures, Y Combinator.
Will Ochre Bio IPO soon?
No public IPO plans have been announced for Ochre Bio.
How can I track Ochre Bio secondary market activity?
Caplight tracks bids, offers, and trades in Ochre Bio's shares on secondary markets.